BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ZContent.net//ZapCalLib 1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
SUMMARY:SYNTHETIC CANNABINOIDS: SEPARATION AND DETECTION OF NEW COMPOUNDS
LOCATION:Virtual Seminar
TZID:America/Denver
DTSTART:20200001T000000
UID:2026-03-15-23-04-24@natsci.colostate.edu
DTSTAMP:20260315T230424
Description:Literature Seminar\n\nThe 2012 Food and Drug Administration Saf
 ety and Innovation Act placed 26 types of cannabinoid receptor agonists\, 
 also known as synthetic cannabinoids (SCs) into Schedule 1 of the Controll
 ed Substances Act. This decision was made due to SCs high probability of c
 ausing adverse health effects\, like reduced blood supply to the heart\, k
 idney damage\, seizures\, and even death.1-3 Despite this\, the SC industr
 y has frequently altered the chemical structure of their products to avoid
  the ban and have continued selling under different names and brands.1 Tes
 ting for SC metabolites in humans differs from conventional cannabinoid te
 sts (immunoassays)\, due to the structural diversity of SCs.4 A rising met
 hod for identification of these new compounds and their metabolites is liq
 uid chromatography coupled with quadrupole-time-of-flight mass spectrometr
 y (LC-QTOF). The study discussed used LC-QTOF to identify the metabolites 
 of (1-(cyclohexylmethyl)-1H-indol-3-yl)-(2\,2\,3\,3-tetramethylcyclopropyl
 )methanone (TMCP-CHM) and the product of its thermal degradation. Both in 
 vitro and in vivo studies were performed\, and the products analyzed using
  LC-QTOF. The major metabolic pathways were identified\, and the results o
 f the in vivo and in vitro studies were compared to a study performed on a
  compound with the TMCP moiety in human urine. This led to the identificat
 ion of a convenient target for routine analysis and a trend in the metabol
 ism of three compounds containing the TMCP moiety.5 With this study as a p
 revalent example\, it was determined that LC-QTOF is a more ideal method f
 or separation and primary identification of SCs and their metabolites in h
 uman urine in comparison to immunoassays and other industry standards\, su
 ch as gas chromatography mass spectrometry (GC-MS) or liquid chromatograph
 y triple quadrupole mass spectrometry (LC-QQQ).\n\n&nbsp\;\n\n 	Hudson\, S
 \; Ramsey\, J. The emergence and Analysis of Synthetic Cananbinoids. Drug 
 Testing and Analysis 2011\, 3 (7-8)\, 466-478.\n 	Food and Drug Administra
 tion Safety and Innovation Act\; 112 Congress\, 2012\; Public Law No. 112-
 114\n 	National Institute on Drug Abuse. Synthetic Cannabinoids (K2/Spice)
  Drug Facts. https://www.drugabuse.gov/publications/drugfacts/synthetic-ca
 nnabinoids-k2spice\n 	Franz\, F.\; et. al. Immunoassay Screening In Urine 
 for Synthetic Cannabinoids – An Evaluation of the Diagnostic Efficiency.
  Clinical Chemistry and Laboratory Medicine (CCLM) 2017\, 55 (9).\n 	Grigo
 ryev\, A.\; Kavanagh\, P\; Labutin\, A.\; Pechnikov\, A.\; Dowling\, G.\; 
 Shevyrin\, V.\; Krupina\, N. Tentative Identification of the Metabolites o
 f (1-cyclohexylmethyl)- 1H-indol-3-yl)-(2\,2\,3\,3-tetramethylcyclopropyl)
 methanone\, and the product of its thermal degradation\, by in vitro and i
 n vivo methods. Drug Testing and Analysis 2019\, 11 (9)\, 1387-1402\n\n&nb
 sp\; 4:30 pm
END:VEVENT
END:VCALENDAR